Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Penile Neoplasms 1Condylomata Acuminata 1Anus Neoplasms 1

Interventions

fludarabine 5Cyclophosphamide 5aldesleukin 4fludarabine phosphate 2entinostat 2aflibercept 2Radiotherapy 2Adoptive Transfer 2rocakinogene sifuplasmid 1ripretinib 1pembrolizumab 1oncogene protein E7, Human papillomavirus type 16 1durvalumab 1bintrafusp alfa protein, human 1Vorinostat 1Vaccines, Synthetic 1VGX-3100 1Ritonavir 1Quality of Life 1Psychiatric Rehabilitation 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1MEDI0457 1Isotretinoin 1Interleukin-2 1Interferon-alpha 1Indinavir 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Penile Neoplasms × Vaccines, Synthetic × Gastrointestinal × Clear all
NCT06465914 2024-12-12

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Active not recruiting
9,000 enrolled
GastrointestinalGenitourinary

Anus Neoplasms, Condylomata Acuminata, Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡